CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The MHT-ImmunoEnhancer project aims to improve glioblastoma treatment by combining magnetic hyperthermia with immunotherapy targeting myeloid-derived suppressor cells. This dual approach seeks to enhance anti-tumor immune responses and reduce tumor growth.
Glioblastoma (GBM) is one of the most lethal and untreatable human tumours, and is characterized by its extremely poor prognosis.
Conventional therapies, including surgery, radiotherapy and chemotherapy, have not resulted in major improvements in the survival, due to high recurrence and tumour spreading.
Therefore, there is an urgent need to develop new effective therapies to improve patient survival.
The establishment of an immunosuppressive tumour microenvironment (TME) in GBM is known to limi…
FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
